Trial Profile

Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Trametinib (Primary) ; Trametinib (Primary) ; Cytarabine; Fludarabine
Indications Juvenile myelomonocytic leukaemia
Focus Adverse reactions

15 Aug 2024 Planned initiation date changed from 30 Nov 2023 to 1 Sep 2024.
16 May 2024 Status changed from not yet recruiting to recruiting.
12 Dec 2023 Trial design assessing combination of trametinib with azacitidine in lower-risk patients and in combination with azacitidine and chemotherapy for high-risk patients. presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com